Overall, these results suggest that our custom nCounter methodology could serve as a standard approach for routine biomarker testing gene fusions (NTRK1,2,3, ALK, RET (Rearranged During Transfection), ROS1 (c-ros Oncogene 1), and MET∆ex14 (Mesenchymal Epithelial Transition exon 14 skipping) in NSCLC patients. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.